
WHAT IS CLAIMED IS:

1. A Form B polymorph of Compound A:

(A)



characterized by having X-ray powder diffraction peaks at

approximately 6.4, 19.3, and 19.9 °2θ using Cu Kα radiation.

2. The Form B polymorph of claim 1, characterized by having X-ray powder diffraction peaks at approximately 6.4, 7.2, 19.3, 19.9, 21.6, 22.1, and 22.6 °2θ using Cu Kα radiation.

3. The Form B polymorph of claim 1, characterized by having an X-ray powder diffraction pattern substantially similar to that set forth in FIG. 1, 6, 8, 10, 15, or 20.

4. The Form B polymorph of claim 1, characterized by an endothermic event with onset at between approximately 133° C. and approximately 138° C. as measured by DSC.

5. The Form B polymorph of claim 1, characterized by a DSC thermogram substantially similar to that set forth in FIG. 16.

6. The Form B polymorph of claim 1, characterized by a weight loss of approximately 0.20% between about 33° C. and about 150° C., as measured by TGA.

7. A pharmaceutical composition comprising a polymorph of claim 1 and a pharmaceutically acceptable carrier or excipient.

8. The Form B polymorph of claim 1, characterized by having X-ray powder diffraction peaks at approximately 6.4, 7.2, 19.3, 19.9, 21.6, 22.1, 22.6, and 24.2 °2θ using Cu Kα radiation.

9. The Form B polymorph of claim 1, characterized by having an X-ray powder diffraction pattern substantially similar to that set forth in FIG. 15.

10. The Form B polymorph of claim 1, characterized by an endothermic event with onset at approximately 136° C. as measured by DSC.